Slides
Page 1
Corvus Corporate Presentation February 2026 The Power to Control Immunity
Page 2
2 Forward - Looking Statements / Safe Harbor This presentation and the accompanying oral presentation contain “forward‐looking” statements related to the potential of the Company’s product candidates including soquelitinib and the interim results from the Phase 1 trial of soquelitinib in patients with atopic dermatitis, the design and timing of initiation of a Phase 2 trial, the advancement of ITK inhibition and the opportunities it provides, and continued advancement of the Company’s clinical pipeline. All statements other than statements of historical fact contained in this presentation are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2025, as well as other documents that may be filed by the Company from time to time with the SEC. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates, the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trails not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and other foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. Such products are currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.
Page 3
3 First - in - Class Immune Modulators with Broad Opportunity in Immune Disease Novel MOA Oral Administration Clinical Stage Pipeline in a Product Strong IP Proven Management Highly selective ITK inhibition; blocks multiple cytokines and rebalances immune response Oral dosing in markets dominated by injectables Broad expansion potential across immune diseases (dermatology, pulmonology, GI and rheumatology) Safety/efficacy seen in placebo-controlled Phase 1 AD; initiating Phase 2 AD with registration Phase 3 PTCL ongoing Composition of matter protection through 2042 Experienced leadership team (rituximab and ibrutinib)
Page 4
4 Soquelitinib : Opportunity Could Parallel Rituximab & Ibrutinib Target the intersection of immune diseases and lymphoma Impacts key elements of immune system Initial clinical value demonstrated in lymphoma Platform opportunity across oncology and inflammatory / immune diseases Developed by members of Corvus Team Ibrutinib (BTK) Rituximab (CD20) Soquelitinib (ITK)
Page 5
5 Advancing ITK’s Broad Therapeutic Potential ITK is a crucial target --- key is specificity Phase 1 AD trial demonstrated positive safety and efficacy results + support novel MOA including immune system rebalancing Phase 2 AD trial planned to initiate in 1Q26 Planning Phase 2 HS and asthma trials ITK Preclinical Phase 1/2 Phase 3Oncology Immunotherapy • PTCL • Solid tumors Immune Disorders • ALPS* Pulmonology/ Inflammation • Asthma Gastroenterology • IBD Fibrotic • Systemic sclerosis Dermatology • Atopic dermatitis • Hidradenitis suppurativa Rheumatology / Autoimmune *NIAID sponsored POC Study
Page 6
6 Soquelitinib Blocks Th2 and Th17 Modulation of T cell differentiation ITK involved in T cell differentiation Th2 and Th17 cells are involved in autoimmune, inflammatory, fibrotic and allergic diseases Th1 cells play a role in cancer cell and viral elimination APC Naïve CD4+ T cell ITK TH1 T-bet Th17 RORγΤ IL-4 IL-5 IL-13 IL-17 IL-21 IL-22 IL-23 TH2 GATA3 APC Naïve CD4+ T cell ITK TH1 T-bet Th17 RORγΤ Th1 cells play a role in cancer cell and viral elimination IL-4 IL-5 IL-13 Th2 and Th17 cells are involved in autoimmune, inflammatory, fibrotic and allergic diseases IL-17 IL-21 IL-22 IL-23 ITK blockade leads to reduction in Th2, Th17 and cytokines TH2 GATA3
Page 7
7 ITK involved in T cell differentiation Th2 and Th17 cells are involved in autoimmune, inflammatory, fibrotic and allergic diseases Th1 cells play a role in cancer cell and viral elimination APC Naïve CD4+ T cell ITK TH1 T-bet Th17 RORγΤ IL-4 IL-5 IL-13 IL-17 IL-21 IL-22 IL-23 TH2 GATA3 APC Naïve CD4+ T cell ITK TH1 T-bet Th17 RORγΤ IL-4 IL-5 IL-13 Blocking ITK results in increase in Tregs and decrease in Th17 IL-17 IL-21 IL-22 IL-23 ITK blockade leads to switch to Treg TH2 GATA3 Treg Foxp3 Sci Signal 17:1, 2024 (DOI: 10.1126/scisignal.adh2381) PLOS ONE 14 (4): 1, 2019 (https://doi.org/10.1371/journal.pone.0215963) ITK Regulates Switch from Th17 to Tregs R ebalancing immunity leads to durable responses
Page 8
8 Soquelitinib is Highly Selective for ITK Kinase Binding Comparison Soquelitinib IbrutinibSpecificity of Binding Drug Discovery 2024, 1:2
Page 9
9 Soquelitinib Effects Multiple Inflammatory Pathways Comparison to other agents Restores immune balance by enhancing T regs Inhibits cells responsible for production and control of many inflammatory cytokines Th2 Th17 ILC2 Treg IL-4 IL-5 IL-13 IL-31 IL-17 IL-21 IL-22 SOQUELITINIB DUPIXENT® EBGLYSS NEMLUVIO® RINVOQ® SOQUELITINIB
Page 10
10 Soquelitinib Broad Opportunities in Multiple Immune Diseases Eosinophilic Granulomatosis Polyangiitis Hypereosinophilic syndrome Psoriasis Psoriatic arthritis Ankylosing spondylitis Hidradenitis suppurativa Th2 Driven Diseases Asthma Atopic dermatitis Eosinophilic esophagitis Prurigo nodularis COPD w/ eosinophilia Rhinitis with polyposis IL-17 Driven Diseases IL-5 Driven Diseases Systemic sclerosis Pulmonary fibrosis Inflammatory bowel disease Autoimmune lymphoproliferation syndrome (ALPS) Graft vs Host Disease Fibrotic / Other Inflammatory Diseases
Page 11
11 Large and Growing I&I Market w/ Unmet Need for Orals Only 4% of current $110B market attributed to orals 30M $170B I&I Market Projected2 Significant opportunity for orals3 2. Evaluate Pharma. 3. JNJ Business Review Dec 2023 (n=398 M/S Psoriasis; 75% switch) . Stein Gold et al, Fall Clinical Dermatology Conference, 2025 ~50% of systemic-eligible PsO pts & derms prefer oral tx; >90% of injectable pts would switch with comparable eff/safety. 130 Million I&I Patients1 20M Eligible for Advanced Treatments 12-29-25 12/29/25 AD 60M Asthma Psor IBD IPF SSHS 30M 15M 2.5M .25M.2M1.2M 23M COPD TH2 TH17 1. Evaluate Pharma. Sanofi R&D investor Day 2023
Page 12
12 Results Show Soquelitinib Could Become a Leading Oral Therapy for Atopic Dermatitis Deeper, Durable Responses Cohort 4 showed additional clinical benefit from longer 8-week treatment vs. cohorts 1-3 Longer follow up of cohort 3 show disease remission for 3-months post- treatment EASI 75: 75% of patients EASI 90: 25% of patients IGA 0/1: 33% of patients Mean EASI reduction: 72% Consistent safety with cohorts 1-3 Positive Clinical Results Biomarkers Support ITK Novel MOA Immune rebalancing: new biomarker data shows soquelitinib modulates Treg cells and cytokine signaling Active in Challenging Patients Cohorts 1-4 demonstrate safety and efficacy in patients who received prior systemic therapies, including those who were treatment resistant
Page 13
13 Increasing Efficacy and Deeper Response with Continued Dosing (8 week dosing vs 4 week dosing) Soquelitinib vs. Placebo Endpoints (EASI 75, EASI 90, IGA 0 or 1) 0 25 33 50 20 75 0 8 0 8 0 25 0 25 17 25 0 33 0 10 20 30 40 50 60 70 80 PBO Cohorts 1-3 (n=12) SQL Cohort 1 (n=12) 100 mg BID SQL Cohort 2 (n=12) 200 mg QD SQL Cohort 3 (n=12) 200 mg BID PBO Cohort 4 (n=10)* SQL Cohort 4 (n=12) 200 mg BID % Patients EASI 75 EASI 90 IGA 0 or 1 4 weeks 8 weeks *2 placebo patients missed the Day 56 visit and are not included. They did return for later visits and did not achieve EASI 75 at any time point. If included in the placebo analysis the 8-week EASI 75 is 17%.
Page 14
14 Atopic Dermatitis Placebo Control Phase 1 Design Participants with moderate to severe AD N = 72 Cohort 1 N =16 Cohort 2 N = 16 Cohort 3 N = 16 Cohort 4 N = 24 Soquelitinib 100 mg BID N = 12 Placebo N = 4 Soquelitinib 200 mg QD N = 12 Placebo N = 4 Soquelitinib 200 mg BID N = 12 Placebo N = 4 Soquelitinib 200 mg BID N = 12 Placebo N = 12 Randomized 3:1 Randomized 3:1 Randomized 3:1 Randomized 1:1 • Endpoints: • Primary: safety • Secondary: % change in EASI, EASI75, EASI90, IGA 0 or 1 • Design • Blinded with placebo • No concomitant topical steroids • 28 day treatment for cohorts 1-3 (3:1 randomization) • 56 day treatment for cohort 4 (1:1 randomization) • Off treatment follow up • Prior systemic therapy allowed • 17 sites all U.S. Study Design 4 weeks treatment At least 1 prior topical or systemic therapy 8 weeks treatment 4 weeks treatment 4 weeks treatment
Page 15
15 4-week 8-week Cohorts 1 and 2 Cohort 3 Cohorts 1–3 Cohort 4 Soquelitinib 100 mg BID or 200 mg QD (n=24) Soquelitinib 200 mg BID (n=12) Placebo (n=12) Soquelitinib 200 mg BID (n=12) Placebo (n=12) Age, mean (range), yrs 44.4 (21–66) 46.4 (25–71) 38.8 (20–62) 40.5 (18–69) 42.3 (21–67) Gender, male n (%) 14 (58.3) 4 (33.3) 7 (58.3) 6 (50) 7 (58.3) Race/ethnicity, n (%) Asian Black or African American White Hispanic or Latino Not Reported 2 (8.3) 13 (54.2) 4 (16.7) 5 (20.8) 0 (0) 0 (0) 5 (41.7) 4 (33.3) 2 (16.7) 1 (8.3) 1 (8.3) 5 (41.7) 2 (16.7) 4 (33.3) 0 (0) 3 (25) 5 (41.7) 3 (25) 1 (8.3) 0 (0) 2 (16.7) 5 (41.7) 2 (16.7) 3 (25.0) 0 (0) Baseline EASI, mean (range) 19.9 (14.7–46.6) 27.2 (18.0–41.5) 21.2 (14.4–46.6) 25.7 (16.6–64.7) 21.9 (16.4–32.9) Baseline IGA 4, n (%) 2 (8.3) 1 (8.3) 2 (16.7) 2 (16.7) 1 (8.3) Prior AD therapies, n (%) Topical corticosteroids Systemic therapies 24 (100) 6 (25) 12 (100) 4 (33.3) 12 (100) 3 (25) 12 (100) 5 (41.7) 12 (100) 7 (58.3) Patient Baseline Characteristics More difficult to treat population with more prior systemic therapies
Page 16
16 Efficacy Results at 4 Weeks Cohorts 1 - 3 Soquelitinib Placebo Cohorts 1 and 2 (N=24) Cohort 3 (N=12) Combined (N=12) Change EASI Mean % Reduction 54.6 64.8 34.4 EASI 50 (%pts) 75 83 58 EASI 75 (%pts) 29 50 0 EASI 90 (%pts) 4 8 0 IGA 0 or 1 (%pts) 21 25 0
Page 17
17 Mean Percent Reduction in EASI Cohorts 1, 2, and 3
Page 18
18 Immune Rebalance Durable remission with increase in Tregs in Cohort 3 • Change from baseline at Day 28 and at Day 58 (n=9 Cohort 1, n=12 Cohort 2, n=12 Cohort 3 green) • Treg: CD45+, CD4+, CD25high, Foxp3+ D1 D28 D58 -50 0 50 100 150 200 % change over baseline SQL Cohort 1 SQL Cohort 2 SQL Cohort 3 PBO Combined Treg increase in blood On Treatment Off Treatment
Page 19
19 Disease Rebounds When Treatment is Stopped Common with JAK inhibitors and others JAMA Derm 155:1371, 2019 • Abrocitinib (JAKi) doses 10, 30, 100, 200 mg QD for 12 weeks • Disease rebounds when treatment stops Percentage change in EASI
Page 20
20 Improvement in Patient Reported Pruritus (PP-NRS) Cohort 3 Demonstrates Clinically Meaningful Reduction in Itch (Evaluable patients with baseline PP-NRS ≥4) Placebo Soquelitinib Cohort 3 1/11 (9%) 4/10 (40%)* *Of the remaining patients, two had baseline PP-NRS of less than 4 and one had incomplete PP-NRS data. ≥ 4-point decrease in PP-NRS at Day 28
Page 21
21 Cohort 4 8-week Soquelitinib (N=12) Placebo (N=12) Change EASI Mean % Reduction 72 40* EASI 50 (%pts) 11 (92) 3 (30)* EASI 75 (%pts) 9 (75) 2 (20)* EASI 90 (%pts) 3 (25) 0 (0) IGA 0 or 1 (%pts) 4 (33) 0 (0) Flare (requiring rescue meds) (%pts) 0 (0) 2 (17) Efficacy Results at 8 Weeks Cohort 4 achieved 75% EASI 75 *2 placebo patients missed the Day 56 visit and are not included. They did return for later visits and did not achieve EASI 75 at any time point. If included in the placebo analysis the 8-week EASI 75 is 17%.
Page 22
22 Mean Percent Reduction in EASI Cohort 4 Increased efficacy with longer duration of treatment (8 weeks)
Page 23
23 Soquelitinib in Patients with Prior Systemic Therapy Prior systemic therapy experience in 35% of patients 35% of patients had prior systemic therapy across all cohorts (n=15 active, 10 placebo) Systemic therapies Soquelitinib N=48 n (%) Placebo N=24 n (%) Dupilumab 6 (13) 5 (21) JAKi 2 (4) 2 (8) Corticosteroids 5 (10) 5 (21) Investigational Drugs 7 (15) 3 (13) ≥ 2 systemic therapies 6 (13) 4 (17)
Page 24
24 Efficacy in Patients with Prior Systemic Therapy (Cohorts 1 – 4) Comparable efficacy in patients with prior systemic therapy Prior Systemic Therapy (Cohorts 1–4)All Patients (Cohorts 1–4)
Page 25
25 Efficacy in Patients with Prior Systemic Therapy (200 mg dose) Comparable efficacy in patients with prior systemic therapy Prior Systemic Therapy (200 mg BID dose)All Patients (200 mg BID dose)
Page 26
26 Response in Systemic Treatment Resistant Patients Cohorts 3 & 4 Study Treatment Age/Gender Prior Treatment Resistant Baseline EASI % EASI change Soquelitinib 60/F Dupixent® 24.6 –91% Soquelitinib 18/M Dupixent®, anti-OX40L 23.8 –96% Soquelitinib 52/M Dupixent®, Methotrexate, Rinvoq® 41.5 –27% Soquelitinib 34/M Dupixent®, anti-OX40, Cibinqo® 23.9 29% Placebo 37/M Dupixent®, Rinvoq® 17.2 Flare (Rescue Meds) Placebo 26/F Dupixent®, Rinvoq® 32.9 Flare (Rescue Meds)
Page 27
27 Safety Summary 4-week 8-week Cohorts 1–3 Cohort 4 Soquelitinib (n=36) Placebo (n=12) Soquelitinib (n=12) Placebo (n=12) Subjects with AEs* 15 (41.7%) 4 (33.3%) 5 (41.7%) 6 (50%) Severe (Grade ≥3) AEs 0 0 0 0 Serious AEs 0 0 0 0 AEs leading to study drug discontinuation 0 0 0 0 *All Grade 1-2 AEs not requiring dose modifications. No clinically significant lab abnormalities. No AEs of conjunctivitis.
Page 28
28 Adverse Events of Interest AEs Soquelitinib N = 48 n (%) Placebo N = 24 n (%) Subjects with AEs 20 (41.7) 10 (41.7) Infections and infestations COVID-19 Skin infection Upper Respiratory 4 (8.3) 1 (2.1) 1 (2.1) 2 (4.2) 3 (12.5) 0 2 (8.3) 1 (4.2) Hepatobiliary disorders 0 0 Renal and urinary disorders 0 0 Eye disorders 0 0 Other 16 (33.3) 8 (33.3)
Page 29
29 -100 -50 0 50 100 Data 1 % change from baseline Soquelitinib Reduces Th2 cells and Effects Multiple Pathways Biomarkers consistent with MOA Change in serum IL-4 Change in serum IL-5 • Serum IL-4 levels over time show late decrease (Cohorts 1–4) • Early reduction in serum IL-5 levels comparing Day 8 to Baseline (Cohorts 1–3 and placebo) • Circulating Th2 cells in blood at Day 28 compared to Baseline (Cohort 1,2) • Reduction in serum IL-17 (Th17 cytokine) and TARC compared to placebo (N=5 active; N=14 placebo) *Th2 cells: GATA3+, STAT6+, c-MAF+, CCR4+, PTGDR2+ (p=0.06) Reduction in Th2 cells scRNA seq* D15 D29 D56 D86 -100 -80 -60 -40 -20 0 Study Day % change from baseline PBO Combined SQL Cohort 3 SQL Cohort 2 SQL Cohort 1 SQL Cohort 4 Cohort 1&2 Cohort 3 PBO -100 -70 -40 -40 30 100 100 300 500 % change from baseline 0.0276 % change from Baseline to Day 56 (Cohort 4, n=5) IL-17 TARC PBO 0.15 –4.1 SQL –14.8 –17.7 Change in IL-17 and TARC
Page 30
30 Competitive Efficacy Data Placebo - adjusted EASI - 75 and IGA 0/1 36 43 15 64 36 50 55 28 30 12 54 22 25 33 N = 462 N = 283 N = 536 N = 458 N = 36 N = 12 N = 12 Dupilumab FDA: Mar 2017 Lebrikizumab FDA: Sep 2024 Nemolizumab FDA: Dec 2024 Upadacitinib FDA: Jan 2022 Soquelitinib Overall Soquelitinib Cohort 3 Soquelitinib Cohort 4 IL-4Rα mAb IL-13 mAb IL-31 mAb ITK Inhib JAK1 Inhib ITK Inhib % Patients 16 Week Phase 3 Data* 4 Week IGA 0/1 IGA 0/1 IGA 0/1 IGA 0/1 IGA 0/1 IGA 0/1 *Source: Package Inserts. For illustrative purposes only: Not a head-to-head analysis. Comparisons of data should be interpreted with caution due to differences in compounds, study designs, subject characteristics, and other factors that may limit direct comp arability.**Includes patients who have received and/or resistant to prior systemic therapies. IGA 0/1 8 Week Phase 1b Data** ITK Inhib
Page 31
31 Randomized Double Blind Phase 2 Trial Plan start in Q1 2026 Study Design SQL 200 mg QD SQL 200 mg BID SQL 400 mg QD Placebo Eligibility Endpoints • Moderate to Severe AD • ≥ 18 years of age • Chronic AD for ≥ 1 year • EASI score ≥ 16, IGA 3 or 4, ≥ 10% BSA, PP-NRS ≥ 4 • ≥ 1 prior treatment (topical or systemic) 12 Weeks Treatment with Extended 90d Follow-up • N=200 • 1:1:1:1 randomization: • Global study • Primary: % change in EASI from Baseline to W12 • Secondary: ▪ EASI 75 at W12 ▪ IGA 0 or 1 at W12 ▪ ≥ 4 point decrease in PP-NRS at W12 ▪ Safety
Page 32
32 Atopic Dermatitis: Significant Market Opportunity AD Market Projected Sales Patients Eligible for Advanced Therapies Only 10% tx with adv. thera ~ 3M Mod/Severe Patients 30M Atopic Dermatitis (AD) patients in the G7 Potential First In Class ITKi High Unmet Need Safe & Effective SystemicTherapies • Up to 50% patients will fail systemic biologic therapy • Black box warnings and monitoring required with JAKi Oral Dosing for Ease of Administration • Many patients come off therapy within 1 year with injectable therapies Novel Target with Durable Response • Significantly more patients treated as more safe and effective novel targets/MOAs approved (8 blockbuster drugs) $11.7B $28B Source: Evaluate Pharma, Clarivate, Analysts Projections, PharmaProjects Source: Clarivate, Analysts, KOL interviews Novel MOA and Oral 2023 2030
Page 33
33 • Primary: Progression free survival • Secondary: • Overall response rate • Overall survival • Duration of response 1:1 randomization to • Soquelitinib 200 mg po BID • Standard of care chemotherapy: • Belinostat • Pralatrexate Randomized Phase 3 Trial in PTCL Enrolling Potential for first fully FDA approved drug for PTCL N = 150 Eligibility • Relapsed / refractory PTCL • PTCL-NOS • AITL • FHTCL-NOS • FHTCL-Follicular • ALCL • ≥1 and ≤3 prior therapies Clinical Trial Endpoints
Page 34
34 BaselineCycle 3 Responses In Cutaneous T Cell Lymphoma Similar immune characteristics to atopic dermatitis • 63 y.o. female with CTCL • Extensive plaque and nodular skin disease, large cell transformation • PR at first disease assessment (9 weeks) • Continued tumor regression at 25+ mo. • Similarities to atopic dermatitis in terms of cellular composition (Th2)
Page 35
35 Summary and Plans Significant potential in Atopic Dermatitis and beyond Near-term I&I development strategy: • Atopic Dermatitis (Phase 2) • Asthma (Phase 2) • Hidradenitis Suppurativa (P2) Ongoing Phase 3 PTCL trial Immune rebalancing has potential in a wide range of I&I indications • Blocks upstream multiple immune pathways • Modulates immune cell functions Daily oral medication Efficacy comparable to leading biologic and JAKi Durable remission following a short treatment period Active in prior systemic therapies, including treatment resistant Strong safety profile Multiple Value Creation Opportunities Novel MOA and Attractive Profile Strong Clinical Data in Atopic Dermatitis
Page 36
36 Multiple Soquelitinib Value - Driving Milestones Atopic dermatitis Cohort 4 data January 2026 Atopic dermatitis Phase 1 data presentation (submitted) AAD 2026 Atopic dermatitis Phase 1 data presentation (oral) SID 2026 Hidradenitis suppurativa Phase 2 trial initiation 2026 Atopic dermatitis Phase 2 trial initiation Q1 2026 Asthma Phase 2 trial initiation 2026 PTCL Phase 3 interim analysis Year end 2026
Page 37
Corvus Corporate Presentation THANK YOU February 2026 The Power to Control Immunity